Proteinuria and Exposure to Eculizumab in Atypical Hemolytic Uremic Syndrome.
Journal
Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570
Informations de publication
Date de publication:
01 Jun 2023
01 Jun 2023
Historique:
received:
14
10
2022
accepted:
28
02
2023
pmc-release:
01
06
2024
medline:
12
6
2023
pubmed:
14
3
2023
entrez:
13
3
2023
Statut:
ppublish
Résumé
Eculizumab is a monoclonal antibody for the treatment of atypical hemolytic uremic syndrome (aHUS). Kidney damage, a common condition in patients with aHUS, may result in proteinuria. Because proteinuria may affect the pharmacokinetics of therapeutic proteins such as eculizumab, the aim of our study was to investigate the effect of proteinuria on eculizumab pharmacokinetics. This study was an ancillary study of a previously performed pharmacokinetic-pharmacodynamic study of eculizumab in aHUS. Proteinuria, measured as urinary protein-creatinine ratios (UPCR), was investigated as covariate for eculizumab clearance. Thereafter, we evaluated the effect of proteinuria on the exposure to eculizumab in a simulation study for the initial phase and for a 2-weekly and 3-weekly interval in the maintenance phase. The addition of UPCR as a linear covariate on clearance to our base model resulted in a statistically improved fit ( P < 0.001) and reduction of unexplained variability in clearance. From our data, we predicted that in the initial phase, 16% of the adult patients with severe proteinuria (UPCR >3.1 g/g) will have inadequate complement inhibition (classical pathway activity >10%) on day 7 of treatment, compared with 3% of the adult patients without proteinuria. None of the pediatric patients will have inadequate complement inhibition at day 7 of treatment. For the 2- and 3-weekly dosing intervals, we predicted that, respectively, 18% and 49% of the adult patients and, respectively, 19% and 57% of the pediatric patients with persistent severe proteinuria will have inadequate complement inhibition, compared with, respectively, 2% and 13% of the adult patients and, respectively, 4% and 22% of the pediatric patients without proteinuria. Severe proteinuria is associated with a higher risk of underexposure to eculizumab. CUREiHUS, Dutch Trial Register, NTR5988/NL5833.
Sections du résumé
BACKGROUND
BACKGROUND
Eculizumab is a monoclonal antibody for the treatment of atypical hemolytic uremic syndrome (aHUS). Kidney damage, a common condition in patients with aHUS, may result in proteinuria. Because proteinuria may affect the pharmacokinetics of therapeutic proteins such as eculizumab, the aim of our study was to investigate the effect of proteinuria on eculizumab pharmacokinetics.
METHODS
METHODS
This study was an ancillary study of a previously performed pharmacokinetic-pharmacodynamic study of eculizumab in aHUS. Proteinuria, measured as urinary protein-creatinine ratios (UPCR), was investigated as covariate for eculizumab clearance. Thereafter, we evaluated the effect of proteinuria on the exposure to eculizumab in a simulation study for the initial phase and for a 2-weekly and 3-weekly interval in the maintenance phase.
RESULTS
RESULTS
The addition of UPCR as a linear covariate on clearance to our base model resulted in a statistically improved fit ( P < 0.001) and reduction of unexplained variability in clearance. From our data, we predicted that in the initial phase, 16% of the adult patients with severe proteinuria (UPCR >3.1 g/g) will have inadequate complement inhibition (classical pathway activity >10%) on day 7 of treatment, compared with 3% of the adult patients without proteinuria. None of the pediatric patients will have inadequate complement inhibition at day 7 of treatment. For the 2- and 3-weekly dosing intervals, we predicted that, respectively, 18% and 49% of the adult patients and, respectively, 19% and 57% of the pediatric patients with persistent severe proteinuria will have inadequate complement inhibition, compared with, respectively, 2% and 13% of the adult patients and, respectively, 4% and 22% of the pediatric patients without proteinuria.
CONCLUSIONS
CONCLUSIONS
Severe proteinuria is associated with a higher risk of underexposure to eculizumab.
CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER
UNASSIGNED
CUREiHUS, Dutch Trial Register, NTR5988/NL5833.
Identifiants
pubmed: 36913245
doi: 10.2215/CJN.0000000000000145
pii: 01277230-202306000-00012
pmc: PMC10278783
doi:
Substances chimiques
eculizumab
A3ULP0F556
Antibodies, Monoclonal, Humanized
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
759-766Informations de copyright
Copyright © 2023 by the American Society of Nephrology.
Références
US Food and Drug Administration. Drug Approval Package Soliris (Eculizumab), US Food and Drug Administration, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/125166s0000toc.cfm . Accessed on October 3, 2022
Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681–696. doi: 10.1016/s0140-6736(17)30062-4
doi: 10.1016/s0140-6736(17)30062-4
Menne J, Delmas Y, Fakhouri F, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol. 2019;20(1):125. doi: 10.1186/s12882-019-1314-1
doi: 10.1186/s12882-019-1314-1
Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3):701–711. doi: 10.1016/j.kint.2015.11.026
doi: 10.1016/j.kint.2015.11.026
Gatault P, Brachet G, Ternant D, et al. Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule. mAbs. 2015;7(6):1205–1211. doi: 10.1080/19420862.2015.1086049
doi: 10.1080/19420862.2015.1086049
Passot C, Sberro-Soussan R, Bertrand D, et al. Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: lessons from a prospective multicentric study. Br J Clin Pharmacol. 2021;87(5):2236–2246. doi: 10.1111/bcp.14627
doi: 10.1111/bcp.14627
Ter Avest M, Bouwmeester RN, Duineveld C, et al. Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective. Nephrol Dial Transplant. 2023 Feb 13;38(2):362–371. doi: 10.1093/ndt/gfac056
doi: 10.1093/ndt/gfac056
Volokhina E, Wijnsma K, van der Molen R, et al. Eculizumab dosing regimen in atypical HUS: possibilities for individualized treatment. Clin Pharmacol Ther. 2017;102(4):671–678. doi: 10.1002/cpt.686
doi: 10.1002/cpt.686
Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507. doi: 10.2165/11531280-000000000-00000
doi: 10.2165/11531280-000000000-00000
Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576–588. doi: 10.1002/psp4.12224
doi: 10.1002/psp4.12224
Jacobs R, Langer-Jacobus T, Duong M, et al. Detection and quantification of rituximab in the human urine. J Immunol Methods. 2017;451:118–121. doi: 10.1016/j.jim.2017.09.001
doi: 10.1016/j.jim.2017.09.001
Wehling C, Amon O, Bommer M, et al. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol. 2017;187(2):304–315. doi: 10.1111/cei.12890
doi: 10.1111/cei.12890
Roberts BV, Susano I, Gipson DS, Trachtman H, Joy MS. Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease. J Clin Pharmacol. 2013;53(9):919–924. doi: 10.1002/jcph.121
doi: 10.1002/jcph.121
Jansen AME, Sriram JD, Pluim D, et al. Therapeutic exposure and successful response to pembrolizumab in a patient with non-small-cell lung cancer despite significant renal loss due to paraneoplastic nephrotic syndrome. Clin Lung Cancer. 2021;22(2):e220–e223. doi: 10.1016/j.cllc.2020.09.021
doi: 10.1016/j.cllc.2020.09.021
Boyer-Suavet S, Andreani M, Cremoni M, et al. Rituximab bioavailability in primary membranous nephropathy. Nephrol Dial Transplant. 2019;34(8):1423–1425. doi: 10.1093/ndt/gfz041
doi: 10.1093/ndt/gfz041
Liu T, Neuner R, Thompson A, et al. Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: a regulatory perspective. Lupus. 2022;31(4):424–432. doi: 10.1177/09612033221079771
doi: 10.1177/09612033221079771
Bouwmeester RN, Ter Avest M, Wijnsma KL, et al. Case report: variable pharmacokinetic profile of eculizumab in an aHUS patient. Front Immunol. 2020;11:612706. doi: 10.3389/fimmu.2020.612706
doi: 10.3389/fimmu.2020.612706
Noris M, Mele C, Remuzzi G. Podocyte dysfunction in atypical haemolytic uraemic syndrome. Nat Rev Nephrol. 2015;11(4):245–252. doi: 10.1038/nrneph.2014.250
doi: 10.1038/nrneph.2014.250
Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15–39. doi: 10.1007/s00467-015-3076-8
doi: 10.1007/s00467-015-3076-8
Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol. 2017;30(1):127–134. doi: 10.1007/s40620-016-0288-3
doi: 10.1007/s40620-016-0288-3
Bouwmeester RN, Duineveld C, Wijnsma KL, et al. Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study. Kidney Int Rep. 2023;8(1):91–102. doi: 10.1016/j.ekir.2022.10.013
doi: 10.1016/j.ekir.2022.10.013
Duineveld C, Bouwmeester RN, Wijnsma KL, et al. Eculizumab rescue therapy in patients with recurrent atypical hemolytic uremic syndrome after kidney transplantation. Kidney Int Rep. 2023 Feb 13;38(2):362–371. doi: 10.1016/j.ekir.2023.01.016
doi: 10.1016/j.ekir.2023.01.016
Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother. 2004;38(10):1702–1706. doi: 10.1345/aph.1D374
doi: 10.1345/aph.1D374
Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. US Department of Health and Human Services, Centers for Disease Control and Prevention.
Carroll MF, Temte JL. Proteinuria in adults: a diagnostic approach. Am Fam Physician. 2000;62(6):1333–1340.
European Medicines Agency (EMA). Summary of Product Characteristics Eculizumab (Soliris). https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf . Accessed on October 3, 2022
Fogueri U, Cheungapasitporn W, Bourne D, Fervenza FC, Joy MS. Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy. Ann Pharmacother. 2019;53(4):357–363. doi: 10.1177/1060028018803587
doi: 10.1177/1060028018803587
Ardissino G, Tel F, Sgarbanti M, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update. Pediatr Nephrol. 2018;33(3):457–461. doi: 10.1007/s00467-017-3813-2
doi: 10.1007/s00467-017-3813-2
Cugno M, Gualtierotti R, Possenti I, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost. 2014;12(9):1440–1448. doi: 10.1111/jth.12615
doi: 10.1111/jth.12615
Caravaca-Fontán F, Díaz-Encarnación M, Cabello V, et al. Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy. Nephrol Dial Transplant. 2021;37(7):1270–1280. doi: 10.1093/ndt/gfab075
doi: 10.1093/ndt/gfab075
Jodele S, Fukuda T, Mizuno K, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(2):307–315. doi: 10.1016/j.bbmt.2015.10.002
doi: 10.1016/j.bbmt.2015.10.002
Fitzpatrick AM, Mann CA, Barry S, Brennan K, Overell JR, Willison HJ. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nervous Syst. 2011;16(2):84–91. doi: 10.1111/j.1529-8027.2011.00328.x
doi: 10.1111/j.1529-8027.2011.00328.x
Hillmen P, Muus P, Szer J, et al. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2016;91(3):E16–E17. doi: 10.1002/ajh.24280
doi: 10.1002/ajh.24280
Kelly RJ, Höchsmann B, Szer J, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373(11):1032–1039. doi: 10.1056/NEJMoa1502950
doi: 10.1056/NEJMoa1502950